Human bone marrow mesenchymal cells express NG2: possible increase in discriminative ability of flow cytometry during mesenchymal stromal cell identification

被引:42
作者
Kozanoglu, Ilknur [2 ,3 ]
Boga, Can [1 ]
Ozdogu, Hakan
Sozer, Oktay [3 ]
Maytalman, Erkan [3 ]
Yazici, Ayse Canan [4 ]
Sahin, Feride Iffet [5 ]
机构
[1] Baskent Univ, Adana Teaching & Med Res Ctr, Dept Hematol, Fac Med, TR-01250 Adana, Turkey
[2] Baskent Univ, Fac Med, Dept Physiol, TR-01250 Adana, Turkey
[3] Baskent Univ, Adana Teaching & Med Res Ctr, Hematol Res Lab, TR-01250 Adana, Turkey
[4] Baskent Univ, Fac Med, Dept Biostat, TR-01250 Adana, Turkey
[5] Baskent Univ, Fac Med, Dept Med Genet, TR-01250 Adana, Turkey
关键词
Flow cytometry; human bone marrow; mesenchymal stromal cells; NG2; STEM-CELLS; PROTEOGLYCAN;
D O I
10.1080/14653240902923153
中图分类号
Q813 [细胞工程];
学科分类号
摘要
Background aims Mesenchymal stromal cells (MSC) exhibit non-specific hematopoietic cell and/or stromal cell markers (e.g. CD73, CD105 and CD166) that have been used to identify MSC by flow cytometry. Because a neural glial antigen, NG2 (a progenitor cell marker in the central nervous system), is expressed by several tissue cells originating in the mesenchyme but not hematopoietic cells, it might be useful for isolating and identifying MSC. We investigated NG2 expression on culture-expanded MSC by flow cytometry. Methods Human bone marrow (BM) samples taken from 12 donors were cultured for MSC to be used in up to nine serial passages. Using flow cytometry, the neural glial antigen NG2 and commonly used MSC markers CD73, CD105 and CD166, were analyzed on the surface of culture-expanded MSC. The multipotential differentiation of the MSC was examined by adipogenic and osteogenic induction. Results The percentage of cells positive for NG2 was similar to the percentages of cells positive for CD73, CD105 and CD166 in all passages of BM samples. The mean fluorescent intensities of NG2 did not change with culture passage. The MSC was successfully differentiated into adipogenic and osteogenic lines. The cells showed no karyotypic abnormalities. Conclusions NG2 seems to be a promising marker for investigating the biology of MSC.
引用
收藏
页码:527 / 533
页数:7
相关论文
共 21 条
[1]  
Aerts F., 2006, Genetic Engineering of Mesenchymal stem cells, P1
[2]  
Bobis S, 2006, FOLIA HISTOCHEM CYTO, V44, P215
[3]   MESENCHYMAL STEM-CELLS [J].
CAPLAN, AI .
JOURNAL OF ORTHOPAEDIC RESEARCH, 1991, 9 (05) :641-650
[4]  
FRIEDENSTEIN AJ, 1982, EXP HEMATOL, V10, P217
[5]   Isolated allogeneic bone marrow-derived mesenchymal cells engraft and stimulate growth in children with osteogenesis imperfecta: Implications for cell therapy of bone [J].
Horwitz, EM ;
Gordon, PL ;
Koo, WKK ;
Marx, JC ;
Neel, MD ;
McNall, RY ;
Muul, L ;
Hofmann, T .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2002, 99 (13) :8932-8937
[6]   Pluripotency of mesenchymal stem cells derived from adult marrow (vol 418, pg 41, 2002) [J].
Jiang, Yuehua ;
Jahagirdar, Balkrishna N. ;
Reinhardt, R. Lee ;
Schwartz, Robert E. ;
Keene, C. Dirk ;
Ortiz-Gonzalez, Xilma R. ;
Reyes, Morayma ;
Lenvik, Todd ;
Lund, Troy ;
Blackstad, Mark ;
Du, Jingbo ;
Aldrich, Sara ;
Lisberg, Aaron ;
Low, Walter C. ;
Largaespada, David A. ;
Verfaillie, Catherine M. .
NATURE, 2007, 447 (7146) :879-880
[7]   Optimization of a flow cytometry-based protocol for detection and phenotypic characterization of multipotent mesenchymal stromal cells from human bone marrow [J].
Jones, Elena A. ;
English, Anne ;
Kinsey, Sally E. ;
Straszynski, Liz ;
Emery, Paul ;
Ponchel, Frederique ;
McGonagle, Dennis .
CYTOMETRY PART B-CLINICAL CYTOMETRY, 2006, 70B (06) :391-399
[8]   Rapid hematopoietic recovery after coinfusion of autologous-blood stem cells and culture-expanded marrow mesenchymal stem cells in advanced breast cancer patients receiving high-dose chemotherapy [J].
Koç, ON ;
Gerson, SL ;
Cooper, BW ;
Dyhouse, SM ;
Haynesworth, SE ;
Caplan, AI ;
Lazarus, HM .
JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (02) :307-316
[9]   HLA expression and immunologic properties of differentiated and undifferentiated mesenchymal stem cells [J].
Le Blanc, K ;
Tammik, C ;
Rosendahl, K ;
Zetterberg, E ;
Ringdén, O .
EXPERIMENTAL HEMATOLOGY, 2003, 31 (10) :890-896
[10]   Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells [J].
Le Blanc, K ;
Rasmusson, I ;
Sundberg, B ;
Götherström, C ;
Hassan, M ;
Uzunel, M ;
Ringdén, O .
LANCET, 2004, 363 (9419) :1439-1441